Core Viewpoint - WuXi AppTec (02268) has announced a share placement agreement to raise approximately HKD 1.3 billion, primarily aimed at expanding its service capacity and production capabilities in bioconjugates and APIs [1] Group 1: Share Placement Details - The company signed a placement agreement to fully underwrite up to 22.77 million shares at a price of HKD 58.85 per share [1] - The expected net proceeds from this placement are approximately HKD 1.3 billion, with about 90% allocated for expanding service capacity and production, particularly in bioconjugates, APIs, and commercial production [1] - The remaining 10% of the funds will be used for working capital and general corporate purposes [1] Group 2: Subscription Agreement - WuXi AppTec has also entered into a subscription agreement with its controlling shareholder, WuXi Biologics (02269), to issue 24.134 million subscription shares at the same price of HKD 58.85 per share [1] - The net proceeds from this subscription are expected to be around HKD 1.4 billion, with a similar allocation of approximately 90% for expanding service capacity and production [1] - The remaining 10% will also be directed towards working capital needs and general corporate purposes [1]
药明合联早盘涨超5% 公司宣布配股筹资 控股股东药明生物斥资超14亿港元认购